Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 7/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | DRD4 | P21917 | 9/20 | 0.70 |
| ▸ | DRD2 | P14416 | 7/20 | 0.68 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.65 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.59 |
| ▸ | DRD3 | P35462 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3187184 | 0.99 | HTR1A (0.98) | HTR1AKDM4EALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL9843330 | 0.94 | HTR1A (0.88) | HTR1AKDM4EALDH1A1CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL9640147 | 0.93 | HTR1A (0.87) | HTR1AKDM4EALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL9280229 | 0.93 | HTR1A (0.86) | HTR1AKDM4EALDH1A1CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL9639153 | 0.92 | HTR1A (0.85) | HTR1AKDM4EALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL9198697 | 0.87 | HTR1A (0.76) | HTR1AKDM4EALDH1A1CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL9639119 | 0.86 | HTR1A (0.75) | HTR1AKDM4EALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL9282819 | 0.85 | HTR1A (0.73) | HTR1AKDM4EALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL9843542 | 0.84 | HTR1A (0.73) | HTR1AKDM4EALDH1A1CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL9640094 | 0.84 | HTR1A (0.72) | HTR1AKDM4EALDH1A1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| EP-0434561-B1 | 1-Naphthyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1995-10-18 | — | — | EP | claimed |
| US-5143916-A | Hypotensive agents | ADIR ET COMPAGNIE (FR) | 1992-09-01 | — | — | US | claimed |
| EP-0434561-A2 | 1-Naphthyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1991-06-26 | — | — | EP | claimed |
| JP-3291275-A | — | — | None | — | — | JP | disclosed |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | disclosed |
| US-20230414628-A1 | METHODS FOR TREATING DISEASES MEDIATED BY GLUTATHIONE PEROXIDASE 4 | RAMESH SANATH KUMAR (US) | 2023-12-28 | — | — | US | disclosed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| US-20050004105-A1 | Treatment for a attention-deficit hyperactivity disorder | PSYCHOGENCIS, INC. | 2005-01-06 | — | — | US | disclosed |
| EP-1067965-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING CEREBRAL APOPLEXY AND CRANIOCEREBRAL TRAUMA | BAYER HEALTHCARE AG (DE) | 2004-09-29 | — | — | EP | disclosed |
| WO-2004069339-A1 | TREATMENT FOR ATTENTION-DEFICIT HYPERACTIVITY DISORDER | PSYCHOGENICS INC. (US) | 2004-08-19 | — | — | WO | disclosed |
| EP-1067965-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CEREBRAL APOPLEXY AND CRANIOCEREBRAL TRAUMA | Bayer Aktiengesellschaft (DE) | 2001-01-17 | — | — | EP | disclosed |
| EP-0969842-A1 | PHARMACEUTICAL COMPOSITION | R.P. Scherer Limited (GB) | 2000-01-12 | — | — | EP | disclosed |
| WO-1999029346-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CEREBRAL APOPLEXY AND CRANIOCEREBRAL TRAUMA | BAYER AKTIENGESELLSCHAFT (DE) | 1999-06-17 | — | — | WO | disclosed |
| WO-1998042344-A1 | PHARMACEUTICAL COMPOSITION | R. P. SCHERER LIMITED (GB) | 1998-10-01 | — | — | WO | disclosed |
| EP-0434561-B1 | 1-Naphthyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1995-10-18 | — | — | EP | disclosed |
| US-5166157-A | Analgesics, antidepressants or psychological disorders | ADIR ET COMPAGNIE (FR) | 1992-11-24 | — | — | US | disclosed |
| JP-H03291275-A | NEW (1-NAPHTHYL)PIPERAZINE DERIVATIVE, PREPARATION OF THE SAME, AND COMPOSITION OF DRUG INCLUDING THE SAME | ADIR | 1991-12-20 | — | — | JP | disclosed |
| EP-0434561-A2 | 1-Naphthyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1991-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004105-A1 | Treatment for a attention-deficit hyperactivity disorder | HTR1A, HTR5A, HTR2A | HTR1A 1/4885KDM4E 3338/4885ALDH1A1 351/4885 |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | HTR1A 4/4885KDM4E 4347/4885ALDH1A1 913/4885 |
| US-20230414628-A1 | METHODS FOR TREATING DISEASES MEDIATED BY GLUTATHIONE PEROXIDASE 4 | GPX4, GPX1, MPO | HTR1A 3582/4885KDM4E 3107/4885ALDH1A1 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.